2026-04532NoticeWallet

NIH Drops Super-Vaccines: 100% Mouse Protection Against Malaria!

Published Date: 3/9/2026

Notice

Summary

The National Institutes of Health is offering new malaria vaccine inventions for companies to license and develop. These cool nanoparticle platforms show promise in making vaccines super effective, with early tests in mice showing 100% protection. If you’re a business or researcher ready to jump in, now’s the time to connect and start working with these government-owned inventions!

Analyzed Economic Effects

4 provisions identified: 4 benefits, 0 costs, 0 mixed.

NIH Offers Malaria Vaccine Tech For Licensing

The National Institute of Allergy and Infectious Diseases (NIAID/NIH) is offering three engineered nanoparticle vaccine platforms for licensing and commercial development under 35 U.S.C. 209 and 37 CFR part 404. The platforms include a PLP synthase nanoparticle displaying 48 copies of up to 4 proteins, a Cpn60 nanoparticle displaying 28 copies of up to 2 proteins, and a Clp nanoparticle displaying 28 copies of up to 2 proteins. To get unpublished information or pursue a license, contact Chris Kornak (240-565-2632, [email protected]) and a signed Confidential Disclosure Agreement is required; reference HHS Ref. No. E-182-2024-0.

Patent Filings Cover Technology

The technology is covered by patent filings: U.S. Provisional Patent Application No. 63/695,288 filed on September 16, 2024, and PCT Patent Application No. PCT/US2025/046419 filed on September 15, 2025. The notice says foreign patent applications have been filed on selected inventions to extend market coverage and those patent rights may be available for licensing.

Pre-Clinical Data Shows 100% Protection In Mice

Pre-clinical data reported in the notice show that nanoparticles displaying the malaria circumsporozoite protein (CSP) conferred 100% sterilizing immunity in mice, and the work is described as being at the pre-clinical developmental stage. The publication cited is: Shi D, et al., Nat Microbiol. 2026;11(1):67-80, doi:10.1038/s41564-025-02209-y.

Opportunity For Collaborative Research

NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these malaria vaccine nanoparticle technologies. Interested parties should contact Chris Kornak at 240-565-2632 or [email protected] to express interest.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
3/9/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in